Version classiqueVersion mobile

Nutzen-Risiko-Bewertung von Mineralstoffen und Spurenelementen

Andrea Hartwig
Beate Köberle
Bernhard Michalke


The debate on selenium as risk factor for type 2 diabetes: Evidence for interplay of selenium and energy metabolism

Holger Steinbrenner


The essential trace element selenium (Se) has a long track record for anti-diabetic and insulin-mimetic properties. By contrast, more recent epidemiological data have suggested potential pro-diabetic effects of supranutritional Se intake in humans. Animal and cell culture studies have provided evidence that dietary Se compounds and selenoproteins can affect both the pancreatic insulin secretion and the insulin sensitivity of target tissues, thereby interfering with insulin-regulated metabolic pathways. To gain insight into underlying molecular mechanisms, we investigated the transcriptional regulation of the major Se-containing plasma protein selenoprotein P by factors related to carbohydrate metabolism, and vice versa, the influence of Se compounds on the insulin signalling cascade. Liver-derived selenoprotein P (SeP) is crucial for Se homeostasis acting as plasma Se transporter. We identified high glucose and glucocorticoids as positive regulators of hepatic SeP biosynthesis, whereas insulin attenuated SeP expression and secretion. Thus, SeP is regulated like a gluconeogenic enzyme by factors controlling the hepatic glucose factory under physiological and pathophysiological conditions. On the other hand, we showed that Se oversupply causes alterations in insulin-regulated energy metabolism in vitro and in vivo: Sodium selenite, a Se source in dietary supplements, delayed insulin-triggered phosphorylation of protein kinase B (Akt) and FoxO transcription factors and decreased glucose uptake in cultured myocytes. In a small pilot study, healthy male pigs were fed a supranutritional Se diet (0.5 mg Se as Se-enriched yeast/kg). After 16 weeks, fasting plasma concentrations of insulin, cholesterol and triacylglycerols were non-significantly elevated in the Se-supplemented animals, whereas fasting glucose concentrations remained unchanged. Several alterations in expression and/or phosphorylation of transcription factors and enzymes point to a shift to increased lipid turnover in adipose tissue and skeletal muscle, induced by supranutritional Se. Taken together, current epidemiological and mechanistic data suggest a more careful handling of dietary Se supplements, even though supranutritional Se intake is probably not sufficient to induce diabetes in healthy individuals.

Entrées d'index

Note de l’éditeur

Running title: Selenium and diabetes

Texte intégral


1The essential trace selenium (Se) has received attention for a plethora of (assumed) beneficial effects on human health and its unique biochemistry [1, 2]. Se is a constituent of the 21st proteinogenic amino acid selenocysteine (Sec) that is co-translationally incorporated into 25 human selenoproteins [3]. Even though the selenoproteome is rather small, biosynthesis of selenoproteins has been shown to be essential for mammals: transgenic mice with a disrupted selenocysteine-tRNASec gene exhibit early embryonic lethality [4]. Humans, whose selenoprotein biosynthesis is impaired due to a rare heterozygous defect in the Sec insertion sequencebinding protein (SECIS) 2 gene, suffer from a multisystem disorder [5]. Many selenoproteins are enzymes with one Sec residue in their active center. Glutathione peroxidases (GPx) and thioredoxin reductases (TrxR) contribute to degradation of reactive oxygen species (ROS) and regulation of the cellular redox homeostasis [2]. Iodothyronine deiodinases (DIO) are involved in the synthesis of thyroid hormones [6]. Seven selenoproteins are localized in the endoplasmic reticulum, where they contribute to the quality control of protein folding and the regulation of calcium homeostasis [7]. Selenoprotein P (SeP) contains up to 10 Sec residues and serves mainly as plasma Se transporter [8].

2The biosynthesis of several key selenoproteins such as GPx1 and SeP decreases when Se supply is low [9,10]. Concentrations of the two major selenoproteins in plasma are used as biomarkers of Se status: Maximal GPx3 activity in plasma is achieved at a daily intake of ~70 µg Se [11], whereas SeP plasma levels reach a plateau at ~105 µg Se/day [12]. In Germany and in most other European countries, the average Se intake from the habitual diet (< 50 µg Se/day) is below those levels, but within the recommended range for adequate nutrition of humans (30 to 85 µg Se/day) [1, 13]. Compared to Europe, Se intake in the U.S. is much higher with 93 and 134 µg/day for males and females, respectively [1, 13]. Overt Se deficiency occurs very rarely in humans. Nevertheless, the consumption of Se-enriched dietary supplements is common in Europe and more so in the U.S., where one-third of the population regularly ingests multivitamin/mineral supplements [14]. Supplements can provide an additional 10-200 µg Se/day, in form of inorganic Se compounds such as sodium selenite and selenate as well as organic Se-compounds, e.g. Se-enriched yeast and garlic containing selenomethionine and gamma-glutamyl-Semethylselenocysteine [1, 15].

3Adequate and/or supranutritional Se intake has been proposed to be beneficial in terms of cancer prevention, dating from a landmark study in the 1970s that reported an inverse correlation of Se intake levels with cancer mortality among individuals from 27 countries [16]. Moreover, Se might be useful for protection against oxidative stress-related chronic diseases of the cardiovascular system and the brain and in the therapy of inflammatory disorders, viral diseases and sepsis [1, 2, 17]. There is increasing evidence that Se may delay the inflammatory process in auto-immune thyroid disease [18]: a recent study showed an improved quality of life and a slower progression of orbitopathy in patients with Graves’ disease (M. Basedow), who were supplemented with 200 µg selenite/day [19]. On the other hand, Se has a very narrow therapeutic window and a U-shaped dose-response curve. Cases of Se toxicity have been observed in humans and animals consuming plants grown at Se-rich soil or after accidental ingestion of very high Se doses [1]. Currently, the “tolerable upper intake level” is set at 300-450 µg Se/day for adults [1, 13]. To assess the prospects of dietary Se supplementation for human health, it should also be taken into account that Se intake above nutritional requirements could trigger adverse side-effects even below toxic levels.

Epidemiological evidence in regard to selenium as risk factor for type 2 diabetes

4The much discussed Nutritional Prevention of Cancer (NPC) trial has shown that there is probably no light without shadow when Se shall be used for dietary supplementation: In order to examine whether Se could suppress the recurrence of skin cancer, 1312 patients from the Eastern U.S. with a history of basal cell or squamous cell carcinomas of the skin received for 4.5 years either 200 µg Se/day in the form of Se-yeast or a placebo [20]. On the one hand, the NPC trial provided strong evidence for a tumor-preventive capacity of Se by revealing decreased overall cancer mortality and a lower incidence of prostate and colorectal cancer in Se-supplemented male subjects with relatively low (< 122 ng/mL baseline plasma Se) initial Se status [20, 21]. On the other hand, Se-supplemented NPC participants with high baseline plasma Se levels (> 122 ng/mL; top tertile) were more likely to develop type 2 diabetes mellitus (T2DM) than those assigned to placebo [22]. An ongoing discussion regarding the safety of dietary Se supplements has arisen from this unexpected finding.

5In comparison to the NPC trial, the much larger selenium and vitamin E cancer prevention trial (SELECT) found that the risk to develop T2DM was slightly increased in the group of participants with daily administration of 200 µg L-selenomethionine. However, the increase in diabetes risk was non-significant [23], and this was confirmed by a recent follow-up of SELECT [24]. SELECT was carried out in healthy U.S. American men at the age ≥ 50 years, whose baseline plasma Se levels were even higher than in the participants of the NPC trial, ranging from 122 to 152 ng/mL [23]. According to two recently published small intervention studies, a short-term (6 weeks) dietary Se supplementation of healthy humans did not induce T2DM or was even beneficial: 150 µg Se/day in the form of dairy-Se or Se-yeast did not cause an increase in fasting plasma glucose concentrations [25]. In comparison to the placebo group, HOMA-IR (homeostatic model assessment of insulin resistance) values were significantly lower in volunteers, who received 200 µg Se/day in the form of Se-yeast [26].

6The majority (4 out of 6) of cross-sectional studies found a positive association between serum/plasma Se levels and T2DM. High serum/ plasma Se levels were associated with increased fasting plasma glucose concentrations and/or increased total and LDL cholesterol concentrations in plasma [27-32]: Two of the four studies showing such positive associations were carried out in the U.S. (NHANES III and NHANES 2003-4) [27, 28], whereas the other two studies (SU.VI.MAX and Olivetti Heart Study) examined European populations [29, 30]. No significant associations were detected in the French EVA study and in a study from Singapore [31, 32]. In contrast, lower Se levels in toenails were reported among diabetic men with or without cardiovascular disease than among healthy participants of the U.S. American Health Professionals Follow-Up Study [33].

7Longitudinal studies found no evidence for a diabetogenic role of Se in humans: a prospective analysis was undertaken to examine associations between serum Se concentrations and cardiometabolic risk factors in an 8-year follow-up of the Italian Olivetti Heart Study. However, baseline Se levels did not predict changes in plasma cholesterol concentrations between the baseline and follow-up examinations [30]. A 9-year follow-up of the French EVA study revealed a protective effect of high serum Se levels at baseline against the later occurrence of impaired fasting glucose that was specific for males [34].

8Recently, we measured plasma adiponectin concentrations, a surrogate marker of insulin resistance and T2DM [35], in the elderly (60-74 years) participants of the UK Prevention of Cancer by Intervention with Selenium (PRECISE) trial. There was an inverse cross-sectional association between baseline plasma Se and adiponectin levels. However, Se supplementation for 6 months with 100, 200 or 300 µg Se/day in form of Se-yeast did not affect the adiponectin concentrations in plasma, arguing against Se-induced development of insulin resistance in this population [36].

Modulation of insulin secretion and signalling by selenium and selenoproteins

9Insulin resistance and an impaired insulin secretory capacity due to progressive loss of pancreatic beta cell mass are hallmarks in the pathogenesis of type 2 diabetes mellitus. Supranutritional Se intake might contribute to the development of T2DM, as Se compounds and selenoproteins are capable of interfering with both insulin biosynthesis in the pancreas and insulin signalling in target tissues [37].

10Expression and activity of glutathione peroxidases is particularly low in pancreatic islets, exhibiting only 5% of the values in liver [38]. Sodium selenite and selenate have been shown to stimulate biosynthesis and secretion of insulin in Min6 insulinoma cells and isolated rat islets in vitro, probably by increasing GPx activity [39]. Paradoxically, an increase in GPx1 activity in pancreatic beta cells can elicit opposing metabolic outcomes in vivo [40]. Beta cells of mice with global transgenic over expression of GPx1 were hypertrophic, showing elevated insulin production and secretion. However, these alterations resulted in hyperinsulinemia, insulin resistance and obesity in aged animals [41]. In other animal models, increased GPx1 activity/expression had beneficial effects: Beta cell-specific GPx1 overexpression ameliorated hyperglycemia in db/db mice and in streptozotocin-treated mice [42]. An adaptive increase in expression of antiapoptotic proteins and antioxidant enzymes including GPx1 has been proposed to contribute to survival of hypertrophic beta cells during chronic hyperglycemia in mice [43].

11Earlier studies in the 1990s reported that high doses of the Se compounds sodium selenate and sodium selenite elicit insulin-mimetic effects in adipocytes and hepatocytes: 1 mM selenate stimulated glucose uptake in isolated rat adipocytes [44], and 10 µM selenite counter-acted glucagonstimulated glycogen breakdown in the isolated perfused rat liver [45]. More recently, we compared the influence of four Se compounds (selenite, selenate, selenomethionine and methylseleninic acid) on insulin signalling and glucose uptake in skeletal muscle cells in vitro: at adoseof 1µM, selenite and methylseleninic acid delayed insulin-induced phosphorylation of protein kinase B (Akt) and forkhead box protein class O (FoxO) transcription factors in L6 rat myotubes, whereas selenate and selenomethionine had no effect. Basal and insulin-stimulated glucose uptake in L6 myotubes was also attenuated by selenite and methylseleninic acid. In contrast, selenomethionine stimulated glucose uptake, but only at a high dose of 100 µM [46].

12Patients with genetically impaired biosynthesis of selenoproteins exhibit enhanced systemic and cellular insulin sensitivity [5]. Two selenoproteins, GPx1 and selenoprotein P (SeP), have been reported to suppress the canonical insulin-induced signalling cascade in hepatocytes and myocytes [37]. GPx1 reduces hydrogen peroxide (H2O2) [9] that serves as second messenger to enhance early insulin signalling and to stimulate insulininduced glucose uptake by transient inhibition of counter-regulatory phosphatases [47, 48]. As Se transport protein, SeP delivers Se for intracellular biosynthesis of GPx1 and other selenoproteins [8]. SeP has been shown to impair insulin signalling and to dys-regulate carbohydrate metabolism in hepatocytes and myocytes [49]. Knock-out of GPx1 in mice resulted in improved insulin-induced phosphorylation of Akt due to increased ROS generation and oxidation (inactivation) of the dual specificity protein phosphatase PTEN, and it protected the rodents from insulin resistance provoked by a high-fat diet [50]. Conversely, elevated GPx activity in the liver of sodium selenate-supplemented rats was associated with increased activity of protein tyrosine phosphatase 1B (PTP-1B) [51]. In addition to GPx1 and SeP, other selenoproteins such as selenoprotein S and methionine sulfoxide reductase have recently been proposed to be involved in the dys-regulation of carbohydrate metabolism induced by supranutritional Se intake [52].

13We compared the expression of enzymes and transcription factors related to energy metabolism in major insulin target tissues of healthy male pigs fed either an adequate-Se (0.17 mg Se/kg) or a supranutritional-Se (0.5 mg Se/kg as Se-yeast) diet. After 16 weeks, fasting plasma concentrations of insulin, cholesterol and triacylglycerols were non-significantly increased in the Se-supplemented animals. Fasting glucose concentrations did not differ between the groups. We did not observe molecular alterations in the liver. In skeletal muscle of the supranutritional-Se pigs, pyruvate kinase was down-regulated, whereas the transcription factors FoxO1a and PGC-1α were up-regulated. In visceral fat of the supranutritional-Se pigs, mRNA levels of the transcription factor SREBP1 were increased and basal phosphorylation of protein kinases (Akt, AMPK, MAPKs) was affected. This pattern suggests a shift to increased lipid turnover in adipose tissue and skeletal muscle of the Se-supplemented animals. However, supranutritional Se was not sufficient to induce type 2 diabetes mellitus [53].

Modulation of selenoprotein biosynthesis by factors related to energy metabolism

14Alternatively, the observed cross-sectional associations between high plasma Se levels and hyperglycemia/dyslipidemia might arise from alterations in Se homeostasis and biosynthesis of selenoproteins as a side effect of a dys-regulated energy metabolism. Selenoprotein P contains around 60% of total Se in human plasma [54]. The vast majority of SeP circulating in plasma derives from the liver [8, 55]. Indeed, hepatic SeP biosynthesis has been shown to be increased under hyperglycaemic conditions: we reported that cultivation of isolated rat hepatocytes in the presence of high glucose concentrations (25 mmol/L vs. 11 mmol/L glucose) stimulated SeP mRNA expression and secretion [56]. A subsequent study corroborated and extended these findings by demonstrating up-regulated hepatic SeP expression by high glucose and palmitate as well as elevated SeP mRNA levels in the liver of animal T2DM models [49]. This might also explain observations of elevated SeP serum levels in individuals with prediabetes and T2DM [49, 57].

15We found that the human SeP promoter contains a functional binding site for FoxO transcription factors [58]. FoxO1a and FoxO3 are involved in the control of the hepatic glucose factory by increasing the transcription of gluconeogenic enzymes through interaction with its co-activator PGC-1α and the transcription factor HNF-4α [59, 60]. We also identified a binding site for HNF-4α at the human SeP promoter, and we showed that SeP transcription is controlled by interaction of PGC-1α with FoxO1a and HNF-4α [61]. This explains both the observed down-regulation of SeP expression in hepatocytes by insulin and its up-regulation by glucocorticoids and high glucose [56, 58, 61]. Based on these results, we developed the concept that SeP is regulated in hepatocytes like a gluconeogenic enzyme [37, 61]. In agreement with this idea, SeP mRNA levels in the liver of mice have been shown to be increased by fasting and to be decreased 1 h after feeding [49]. A recent study provided additional support by demonstrating that methylation of the involved transcription factors is required for transcription of both gluconeogenic enzymes and SeP [62].

Concluding remarks

16The epidemiological evidence for a diabetogenic role of selenium in healthy humans is still rather weak and controversial, even though the majority of cross-sectional observations point to an association of high plasma/serum Se levels with biomarkers of type 2 diabetes mellitus such as hyperglycemia, dyslipidemia and low adiponectin plasma levels [27, 36, 37, 63-65]. Mechanistic studies have provided alternative explanations for the observed cross-sectional associations: dietary Se oversupply may affect pancreatic insulin secretion and insulin sensitivity of target tissues, probably through inducing abundant expression of selenoproteins. Conversely, hepatic biosynthesis of selenoprotein P, the major Se-containing protein in plasma, is increased under hyperglycaemic conditions.

17Despite the induction of some alterations in energy metabolism, commonly applied selenium doses -as ingested through dietary supplements -are probably not sufficient to induce overt type 2 diabetes in healthy individuals. Nevertheless, it is recommended that individuals with high Se status should not ingest Se-containing supplements, as optimising, rather than maximising, exposure is the key to benefit most from Se while avoiding potential adverse effects [65].


18I would like to thank Drs. H. Sies, B. Speckmann, A. Pinto and A.M. Rajalin for the excellent teamwork in our selenium group in Düsseldorf. Further-more, I thank Drs. L.O. Klotz (University of Alberta, Canada), M.P. Rayman (University of Surrey, Great Britain) and S. Schinner (University Hospital Düsseldorf, Germany) for cooperation and many helpful discussions. This work was supported by Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany (STE 1782/2-1, STE 1782/2-2, Schwerpunktprogramm 1087 „Selenoproteine“ (Si 255/11) and Sonder-forschungsbereich 575/B4).



[1] Fairweather-Tait SJ, Bao Y, Broadley MR, et al. Selenium in human health and disease. Antioxid Redox Signal 14: 1337-1383, 2011.

[2] Steinbrenner H, and Sies H. Protection against reactive oxygen species by selenoproteins. Biochim Biophys Acta 1790: 1478-1485, 2009.

[3] Kryukov GV, Castellano S, Novoselov SV, et al. Characterization of mammalian selenoproteomes. Science 300: 1439-1443, 2003.

[4] Bösl MR, Takaku K, Oshiman M, Nishimura S, and Taketo MM. Early embryonic lethality caused by targeted disruption of the mouse selenocysteine tRNA gene (Trsp). Proc Natl Acad Sci USA 94: 5531-5534, 1997.

[5] Schoenmakers E, Agostini M, Mitchell C, et al. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest 120: 4220-4235, 2010.

[6] Köhrle J. Selenium and the control of thyroid hormone metabolism. Thyroid 15: 841-853, 2005.

[7] Shchedrina VA, Zhang Y, Labunskyy VM, Hatfield DL, and Gladyshev VN. Structure-function relations, physiological roles, and evolution of mammalian ER-resident selenoproteins. Antioxid Redox Signal 12: 839-849, 2010.

[8] Burk RF, and Hill KE. Selenoprotein P-expression, functions, and roles in mammals. Biochim Biophys Acta 1790: 1441-1447, 2009.

[9] Brigelius-Flohé R. Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med 27: 951-965, 1999.

[10] Hill KE, Chittum HS, Lyons PR, Boeglin ME, and Burk RF. Effect of selenium on selenoprotein P expression in cultured liver cells. Biochim Biophys Acta 1313: 29-34, 1996.

[11] Duffield AJ, Thomson CD, Hill KE, and Williams S. An estimation of selenium requirements for New Zealanders. Am J Clin Nutr 70: 896-903, 1999.

[12] Hurst R, Armah CN, Dainty JR, et al. Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 91: 923-931, 2010.

[13] Rayman MP. Food-chain selenium and human health: emphasis on intake. Br J Nutr 100: 254-268, 2008.

[14] Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003-2006. J Nutr 141: 261-266, 2011.

[15] Rayman MP, Infante HG, and Sargent M. Food-chain selenium and human health: spotlight on speciation. Br J Nutr 100: 238-253.

[16] Schrauzer GN, White DA, and Schneider CJ. Cancer mortality correlation studies-III: statistical associations with dietary selenium intakes. Bioinorg Chem 7: 23-31, 1977.

[17] Huang Z, Rose AH, and Hoffmann PR. The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 16: 705-743, 2012.

[18] Schomburg L. Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol 8: 160-171, 2011.

[19] Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 364: 1920-1931, 2011.

[20] Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276: 1957-1963, 1996.

[21] Duffield-Lillico AJ, Reid ME, Turnbull BW, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11: 630-639, 2002.

[23] Stranges S, Marshall JR, Natarajan R, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med 147: 217-223, 2007.

[24] Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301: 39-51, 2009.

[25] Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306: 1549-1556, 2011.

[26] Hu Y, McIntosh GH, Le Leu RK, et al. The influence of selenium-enriched milk proteins and selenium yeast on plasma selenium levels and rectal selenoprotein gene expression in human subjects. Br J Nutr 106: 572-582, 2011.

[27] Alizadeh M, Safaeiyan A, Ostadrahimi A, et al. Effect of L-arginine and selenium added to a hypocaloric diet enriched with legumes on cardiovascular disease risk factors in women with central obesity: a randomized, double-blind, placebo-controlled trial. Ann Nutr Metab 60: 157-168, 2012.

[28] Bleys J, Navas-Acien A, and Guallar E. Serum selenium and diabetes in U.S. adults. Diabetes Care 30: 829-834, 2007.

[29] Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, and Guallar E. Serum selenium concentrations and diabetes in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Environ Health Perspect 117: 1409-1413, 2009.

[30] Czernichow S, Couthouis A, Bertrais S, et al. Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. Am J Clin Nutr 84: 395-399, 2006.

[31] Stranges S, Galletti F, Farinaro E, et al. Associations of selenium status with cardiometabolic risk factors: an 8-year follow-up analysis of the Olivetti Heart study. Atherosclerosis 217: 274-278, 2011.

[32] Coudray C, Roussel AM, Arnaud J, and Favier A. Selenium and antioxidant vitamin and lipidoperoxidation levels in preaging French population. EVA Study Group. Edude de vieillissement artériel. Biol Trace Elem Res 57: 183-190, 1997.

[33] Hughes K, Choo M, Kuperan P, Ong CN, and Aw TC. Cardiovascular risk factors in non-insulin-dependent diabetics compared to non-diabetic controls: a population-based survey among Asians in Singapore. Atherosclerosis 136: 25-31, 1998.

[34] Rajpathak S, Rimm E, Morris JS, and Hu F. Toenail selenium and cardiovascular disease in men with diabetes. J Am Coll Nutr 24: 250-256, 2005.

[35] Akbaraly TN, Arnaud J, Rayman MP, et al. Plasma selenium and risk of dysglycemia in an elderly French population: results from the prospective Epidemiology of Vascular Ageing Study. Nutr Metab (Lond) 7: 21, 2010.

[36] Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000.

[37] Rayman MP, Blundell-Pound G, Pastor-Barriuso R, Guallar E, Steinbrenner H, and Stranges S. A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. PLoS One 7: e45269, 2012.

[38] Steinbrenner H, Speckmann B, Pinto A, and Sies H. High selenium intake and increased diabetes risk: experimental evidence for interplay between selenium and carbohydrate metabolism. J Clin Biochem Nutr 48: 40-45, 2011.

[39] Tiedge M, Lortz S, Drinkgern J, and Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulinproducing cells. Diabetes 46: 1733-1742, 1997.

[40] Campbell SC, Aldibbiat A, Marriott CE, et al. Selenium stimulates pancreatic beta-cell gene expression and enhances islet function. FEBS Lett 582: 2333-2337, 2008.

[41] Lei XG, and Vatamaniuk MZ. Two tales of antioxidant enzymes on β cells and diabetes. Antioxid Redox Signal 14: 489-503, 2011.

[42] McClung JP, Roneker CA, Mu W, et al. Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci U S A 101: 8852-8857, 2004.

[43] Harmon JS, Bogdani M, Parazzoli SD, et al. beta-Cell-specific overexpression of glutathione peroxidase preserves intranuclear MafA and reverses diabetes in db/db mice. Endocrinology 150: 4855-4862, 2009.

[44] Laybutt DR, Kaneto H, Hasenkamp W, et al. Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to betacell survival during chronic hyperglycemia. Diabetes 51: 413-423, 2002.

[45] Ezaki O. The insulin-like effects of selenate in rat adipocytes. J Biol Chem 265: 1124-1128, 1990.

[44] Roden M, Prskavec M, Fürnsinn C, et al. Metabolic effect of sodium selenite: insulin-like inhibition of glucagon-stimulated glycogenolysis in the isolated perfused rat liver. Hepatology 22: 169-174, 1995.

[45] Pinto A, Speckmann B, Heisler M, Sies H, and Steinbrenner H. Delaying of insulin signal transduction in skeletal muscle cells by selenium compounds. J Inorg Biochem 105: 812-820, 2011.

[46] Czech MP, Lawrence JC Jr, and Lynn WS. Evidence for the involvement of sulfhydryl oxidation in the regulation of fat cell hexose transport by insulin. Proc Natl Acad Sci U S A 71: 4173-4177, 1974.

[47] Mahadev K, Zilbering A, Zhu L, and Goldstein BJ. Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1b in vivo and enhances the early insulin action cascade. J Biol Chem 276: 21938-21942, 2001.

[48] Misu H, Takamura T, Takayama H, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 12: 483-495, 2010.

[49] Loh K, Deng H, Fukushima A, et al. Reactive oxygen species enhance insulin sensitivity. Cell Metab 10: 260-272, 2009.

[50] Mueller AS, Klomann SD, Wolf NM, et al. Redox regulation of protein tyrosine phosphatase 1B by manipulation of dietary selenium affects the triglyceride concentration in rat liver. J Nutr 138: 2328-2336, 2008.

[51] Labunskyy VM, Lee BC, Handy DE, Loscalzo J, Hatfield DL, and Gladyshev VN. Both maximal expression of selenoproteins and selenoprotein deficiency can promote development of type 2 diabetes-like phenotype in mice. Antioxid Redox Signal 14: 2327-2336, 2011.

[52] Modulation of insulin secretion and signalling by selenium and selenoproteinstargets related to energy metabolism in skeletal muscle and visceral adipose tissue of pigs. J Inorg Biochem 114: 47-54, 2012.

[53] Burk RF, Early DS, Hill KE, Palmer IS, and Boeglin ME. Plasma selenium in patients with cirrhosis. Hepatology 27: 794-798, 1998.

[54] Carlson BA, Novoselov SV, Kumaraswamy E, et al. Specific excision of the selenocysteine tRNA[Ser]Sec (Trsp) gene in mouse liver demonstrates an essential role of selenoproteins in liver function. J Biol Chem 279: 8011-8017, 2004.

[55] Speckmann B, Sies H, and Steinbrenner H. Attenuation of hepatic expression and secretion of selenoprotein P by metformin. Biochem Biophys Res Commun 387: 158-163, 2009.

[56] Yang SJ, Hwang SY, Choi HY, et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrin Metab 96: E1325–E1329, 2011.

[57] Walter P, Steinbrenner H, Barthel A, and Klotz LO. Stimulation of selenoprotein P promoter activity in hepatoma cells by FoxO1a transcription factor. Biochem Biophys Res Commun 365: 316-321, 2008.

[58] Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423: 550-555, 2003.

[59] Rhee J, Inoue Y, Yoon JC, et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A 100: 4012-4017, 2003.

[60] Speckmann B, Walter PL, Alili L, Reinehr R, Sies H, Klotz LO, Steinbrenner H. Selenoprotein P expression is controlled through interaction of the coactivator PGC-1alpha with FoxO1a and hepatocyte nuclear factor 4alpha transcription factors. Hepatology 48: 1998-2006, 2008.

[61] Jackson MI, Cao J, Zeng H, Uthus EO, and Combs GF Jr. S-Adenosylmethionine Dependent Protein Methylation is Required for Expression of Selenoprotein P and Gluconeogenic Enzymes in Human Hepatocytes. J Biol Chem 287: 36455-36464, 2012.

[62] Mueller AS, Mueller K, Wolf NM, and Pallauf J. Selenium and diabetes: an enigma? Free Radic Res 43: 1029-1059, 2009.

[63] Stranges S, Navas-Acien A, Rayman MP, and Guallar E. Selenium status and cardiometabolic health: state of the evidence. Nutr Metab Cardiovasc Dis 20: 754-760, 2010.

[64] Rayman MP. Selenium and human health. Lancet 379: 1256-1268, 2012.


Institute for Biochemistry and Molecular Biology I, Heinrich-Heine-University Düsseldorf, Universitätsstrasse 1, Geb. 22.03, D-40225 Düsseldorf, Germany


Open access

Rechercher dans OpenEdition Search

Vous allez être redirigé vers OpenEdition Search